Cost-Utility of Sunitinib (SU) for Treatment of Advanced or Metastatic Pancreatic Neuroendocrine Tumors (pNET) in Scotland and Wales

被引：0
|
作者：
Johns, A. [1 ]
Eatock, M. [2 ]
Johal, S. [3 ]
机构：
[1] Pfizer UK, Tadworth, England
[2] No Ireland Canc Ctr, Belfast, Antrim, North Ireland
[3] RTI Hlth Solut, Sheffield, S Yorkshire, England
来源：
NEUROENDOCRINOLOGY | 2012年 / 96卷
关键词：
sunitinib; overall survival; cost-utility; pancreatic net;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：38 / 38
页数：1
相关论文
共 47 条
  • [31] Sunitinib in Tandem With 177Lu-DOTATATE Therapy in Advanced Pancreatic Neuroendocrine Tumor A New Treatment Approach
    Aggarwal, Piyush
    Gunasekaran, Vinisha
    Sood, Ashwani
    Gupta, Kushal
    Das, Chandan Krushna
    Mittal, Bhagwant Rai
    CLINICAL NUCLEAR MEDICINE, 2024, 49 (02) : e85 - e86
  • [32] Peptide Receptor Radionuclide Therapy versus Capecitabine/Temozolomide for the Treatment of Metastatic Pancreatic Neuroendocrine Tumors
    Gujarathi, Rushabh
    Tobias, Joseph
    Abou Azar, Sara
    Keutgen, Xavier M.
    Liao, Chih-Yi
    CANCERS, 2024, 16 (17)
  • [33] Bendamustine Versus Chlorambucil for the First-Line Treatment of Chronic Lymphocytic Leukemia in England and Wales: A Cost-Utility Analysis
    Woods, Beth
    Hawkins, Neil
    Dunlop, William
    O'Toole, Alison
    Bramham-Jones, Steve
    VALUE IN HEALTH, 2012, 15 (05) : 759 - 770
  • [34] Oral Agents for Treatment of Patients with Advanced Pancreatic Neuroendocrine Tumors: Could Pharmaeconomic, Cost-Effectiveness Data Play a Significant Role?
    Barna, Maria Elisa
    Uomo, Ilaria
    Pastorello, Maurizio
    JOURNAL OF THE PANCREAS, 2013, 14 (01): : 102 - 104
  • [35] Cost-utility analysis of 5-fluorouracil and capecitabine for adjuvant treatment in locally advanced rectal cancer
    Katanyoo, Kanyarat
    Chitapanarux, Imjai
    Tungkasamit, Tharatorn
    Chakrabandhu, Somvilai
    Chongthanakorn, Marisa
    Jiratrachu, Rungarun
    Kridakara, Apiradee
    Townamchai, Kanokpis
    Muangwong, Pooriwat
    Tovanabutra, Chokaew
    Chomprasert, Kittisak
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2018, 9 (03) : 425 - 434
  • [36] Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naive Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 Trial
    Grande, Enrique
    Rodriguez-Antona, Cristina
    Lopez, Carlos
    Alonso-Gordoa, Teresa
    Benavent, Marta
    Capdevila, Jaume
    Teule, Alex
    Custodio, Ana
    Sevilla, Isabel
    Hernando, Jorge
    Gajate, Pablo
    Molina-Cerrillo, Javier
    Jose Diez, Juan
    Santos, Maria
    Lanillos, Javier
    Garcia-Carbonero, Rocio
    ONCOLOGIST, 2021, 26 (11) : 941 - 949
  • [37] Olaparib versus Placebo in Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer: A Cost-Utility Analysis from the Canadian Public Payer's Perspective
    Fashami, Fatemeh Mirzayeh
    Levine, Mitchell
    Xie, Feng
    Blackhouse, Gordon
    Tarride, Jean-Eric
    CURRENT ONCOLOGY, 2023, 30 (05) : 4688 - 4699
  • [38] CHOI Criteria Are More Accurate Than RECIST in Advanced Pancreatic Neuroendocrine Tumors Treated with Sunitinib: Data from the CRIPNET-GETNE1504 Study
    Jimenez -Fonseca, P.
    del Valle, Fernandez A.
    Solis, M. P.
    Carbonero, Garcia R.
    Custodio, A.
    Benavent, M.
    Gordoa, Alonso T.
    Matos, I
    Alonso, V
    Lopez, C.
    Viudez, A.
    Carmona-Bayonas, A.
    NEUROENDOCRINOLOGY, 2020, 110 : 167 - 167
  • [39] Efficacy of Sunitinib Correlated with Clinical, Radiological Variables, Dose-Intensity and Treatment Time in Advanced Grade 1-2 Pancreatic Neuroendocrine Tumors (CRIPNET-GETNE Study NCT02841865)
    Jimenez-Fonseca, P.
    Hernandez, Solis M. P.
    del Valle, Fernandez A.
    Garcia-Carbonero, R.
    Matos, I
    Alonso, V
    Custodio, A.
    Alonso, T.
    Sanchez Canovas, M.
    Benavent, M.
    Lopez, C.
    Carmona-Bayonas, A.
    NEUROENDOCRINOLOGY, 2018, 106 : 214 - 214
  • [40] Cost-utility of afatinib and gefitinib as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer
    Wang, Hao
    Zeng, Chenxin
    Li, Xin
    Wang, Youjie
    Li, Xinyi
    Ge, Weihong
    FUTURE ONCOLOGY, 2019, 15 (02) : 181 - 191
12345